These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17692556)

  • 1. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.
    Nagabhushan TL; Maneval DC; Benedict WF; Wen SF; Ihnat PM; Engler H; Connor RJ
    Cytokine Growth Factor Rev; 2007; 18(5-6):389-94. PubMed ID: 17692556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
    Dinney CP; Fisher MB; Navai N; O'Donnell MA; Cutler D; Abraham A; Young S; Hutchins B; Caceres M; Kishnani N; Sode G; Cullen C; Zhang G; Grossman HB; Kamat AM; Gonzales M; Kincaid M; Ainslie N; Maneval DC; Wszolek MF; Benedict WF
    J Urol; 2013 Sep; 190(3):850-6. PubMed ID: 23507396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.
    Navai N; Benedict WF; Zhang G; Abraham A; Ainslie N; Shah JB; Grossman HB; Kamat AM; Dinney CP
    Ann Surg Oncol; 2016 Nov; 23(12):4110-4114. PubMed ID: 27387678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.
    Tao Z; Connor RJ; Ashoori F; Dinney CP; Munsell M; Philopena JA; Benedict WF
    Cancer Gene Ther; 2006 Feb; 13(2):125-30. PubMed ID: 16082384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.
    Benedict WF; Tao Z; Kim CS; Zhang X; Zhou JH; Adam L; McConkey DJ; Papageorgiou A; Munsell M; Philopena J; Engler H; Demers W; Maneval DC; Dinney CP; Connor RJ
    Mol Ther; 2004 Sep; 10(3):525-32. PubMed ID: 15336652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens.
    Connor RJ; Anderson JM; Machemer T; Maneval DC; Engler H
    Urology; 2005 Jul; 66(1):224-9. PubMed ID: 15992886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.
    Yamashita M; Rosser CJ; Zhou JH; Zhang XQ; Connor RJ; Engler H; Maneval DC; Karashima T; Czerniak BA; Dinney CP; Benedict WF
    Cancer Gene Ther; 2002 Aug; 9(8):687-91. PubMed ID: 12136430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    Shore ND; Boorjian SA; Canter DJ; Ogan K; Karsh LI; Downs TM; Gomella LG; Kamat AM; Lotan Y; Svatek RS; Bivalacqua TJ; Grubb RL; Krupski TL; Lerner SP; Woods ME; Inman BA; Milowsky MI; Boyd A; Treasure FP; Gregory G; Sawutz DG; Yla-Herttuala S; Parker NR; Dinney CPN
    J Clin Oncol; 2017 Oct; 35(30):3410-3416. PubMed ID: 28834453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys.
    Veneziale RW; Kishnani NS; Nelson J; Resendez JC; Frank DW; Cai XY; Xie L; Cullen C; Frugone CA; Rosenfeld C; Hubbell J; Maxwell SE; Sugarman BJ; Hutchins B; Maneval D; Treinen KA
    Gene Ther; 2012 Jul; 19(7):742-51. PubMed ID: 21900961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.
    Zhang X; Yang Z; Dong L; Papageorgiou A; McConkey DJ; Benedict WF
    Cancer Gene Ther; 2007 Mar; 14(3):241-50. PubMed ID: 17096027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
    Adam L; Black PC; Kassouf W; Eve B; McConkey D; Munsell MF; Benedict WF; Dinney CP
    J Urol; 2007 May; 177(5):1900-6. PubMed ID: 17437845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in end products of nitric oxide in urine and induction of nitric oxide synthase expression in urinary bladder during intravesical instillations of IFN-alpha2b.
    Mitropoulos D; Deliconstantinos G; Adamakis I; Zervas A; Karakaidos P; Gorgoulis VG
    J Interferon Cytokine Res; 2004 Oct; 24(10):621-6. PubMed ID: 15626159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
    Bercovich E; Deriu M; Manferrari F; Irianni G
    Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
    Kuball J; Wen SF; Leissner J; Atkins D; Meinhardt P; Quijano E; Engler H; Hutchins B; Maneval DC; Grace MJ; Fritz MA; Störkel S; Thüroff JW; Huber C; Schuler M
    J Clin Oncol; 2002 Feb; 20(4):957-65. PubMed ID: 11844817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles.
    Demers GW; Sugarman BJ; Beltran JC; Westreich LN; Ahmed CM; Lau JY; Hong Z; Lanford RE; Maneval DC
    Toxicol Appl Pharmacol; 2002 Apr; 180(1):36-42. PubMed ID: 11922775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
    Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
    Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
    Wu Q; Mahendran R; Esuvaranathan K
    Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructural study of the noninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy.
    Stravoravdi P; Natsis K; Kirtsis P; Retalis G; Konstandinidis E; Polyzonis M
    Eur Urol; 1996; 29(4):477-82. PubMed ID: 8791058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer.
    Frangos DN; Killion JJ; Fan D; Fishbeck R; von Eschenbach AC; Fidler IJ
    J Urol; 1990 Jun; 143(6):1252-6. PubMed ID: 2342197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.